IGC Pharma, Inc. — Form 10-Q
Filed November 6, 2026 · analyzed by the Periodic Agent
10-Q
▼ Likely negative
significance 72/100
What the filing says
On June 30, 2026, IGC Pharma converted two outstanding loans into restricted common stock: Claudia Grimaldi's $281,203 loan converted to 1,041,493 shares, and Ram Mukunda's $286,540 loan converted to 1,061,260 shares, both at $0.27/share (the closing price that day). The shares are restricted securities bearing customary restrictive legends and cannot be sold without registration or exemption. Notably, both Grimaldi and Mukunda hold officer positions (VP/CFO and CEO, respectively) and signed the October 2026 clarification letters and Sarbanes-Oxley certifications.
Why this rating
Debt-to-equity conversion totals $567.7K—3.1% of $18.5M market cap. Modest absolute size, but significant for a micro-cap: eliminates debt burden, reduces cash runway pressure, yet signals prior liquidity stress and dilutes existing shareholders by ~2.1M shares. Officer participation raises governance questions.
Tradability signal
NO TRADE
No trade: price $0.20 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $0.19 ▼ 2.85% | at our read · unknown $0.20 | +10 min · unknown $0.20 ▼ 2.45% | +30 min · unknown $0.20 ▼ 1.00% | +1 hr · unknown $0.20 ▲ 1.00% | +4 hrs · unknown $0.20 ▲ 0.00% |
The stock had already moved +2.93% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.